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We report that a symmetric small-molecule ligand mediates the assembly of antibody light chain variable
domains (VLs) into a correspondent symmetric ternary complex with novel interfaces. The L5* fluorogen
activating protein is a VL domain that binds malachite green (MG) dye to activate intense fluorescence.
Crystallography of liganded L5* reveals a 2:1 protein:ligand complex with inclusiveC2 symmetry, where MG is
almost entirely encapsulated between an antiparallel arrangement of the two VL domains. Unliganded L5* VL
domains crystallize as a similar antiparallel VL/VL homodimer. The complementarity-determining regions
are spatially oriented to form novel VL/VL and VL/ligand interfaces that tightly constrain a propeller conformer
of MG. Binding equilibrium analysis suggests highly cooperative assembly to form a very stable VL/MG/VL
complex, such that MG behaves as a strong chemical inducer of dimerization. Fusion of two VL domains into a
single protein tightens MG binding over 1000-fold to low picomolar affinity without altering the large binding
enthalpy, suggesting that bonding interactions with ligand and restriction of domain movements make
independent contributions to binding. Fluorescence activation of a symmetrical fluorogen provides a selection
mechanism for the isolation and directed evolution of ternary complexes where unnatural symmetric binding
interfaces are favored over canonical antibody interfaces. As exemplified by L5*, these self-reporting
complexes may be useful as modulators of protein association or as high-affinity protein tags and capture
reagents.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
Classical vertebrate immune systems are able
to generate antibodies that specifically recognize
and bind a highly diverse repertoire of immunogens,
including natural and synthetic small molecules.
Immunoglobulin (IgG) heavy chain (VH) and light
chain (VL) variable domains form a heterologous
binding pocket where, typically, amino acids from
both domains contact the small-molecule ligand.
Isolated VH and VL domains bind one another along
an evolutionarily conserved interface found in the
parent IgG, forming a binding cleft flanked at its openthors. Published by Elsevier Ltd.Open access unend by six protein backbone loops, three from each
domain [1]. Molecular recognition capabilities are
largely determined by these loops, termed comple-
mentarity-determining regions (CDRs), which under-
go somatic hypermutation during the immune
response to generate specific high-affinity binding
to the antigen. The VH and VL domains may be
genetically fused via short peptide linkers to create
single chain antibodies (scFvs) that generally retain
the IgG variable region architecture and binding
functionality [2].
We have used scFvs as a platform to develop
fluorescent biosensors and reporters for use in livingJ. Mol. Biol. (2013) 425, 4595–4613der CC BY-NC-ND license. 
Fig. 1. Derivation and directed evolution of L5*. (a) Alignment of L5* with human VL germline progenitor. L5* amino
acids are numbered by the Kabat scheme, and CDRs are identified using the Kabat definitions [61] (CDR1, light green;
CDR2, light blue; CDR3, pink). (b) Directed evolution of the original isolate of L5 [3]. Shown are VL sequences of the seven
isolates chosen for characterization, six of which are genetically unique; there are two instances of L5*, which has acquired
a single point mutation, Ser89 (Kabat). The Ser89 mutation that increases quantum yield 5-fold [7] is highly dominant over
other independent mutations. The Asp50 mutation (Kabat) that increases the affinity to dL5** for MG by ~6-fold [7]
represents a reversion to the germline amino acid.
4596 Malachite Green Dimerizes Antibody VL Domainssystems [3–17]. The technology is based on certain
organic dyes (fluorogens) that are non-fluorescent
when free in solution but become intensely fluorescent
when specifically bound by cognate scFvs (fluorogen
activating proteins, or FAPs) [3,4,7,10,12]. It is thought
that the scFv binding pocket physically constrains
rotation around the methine bonds of the dye
chromophore, promoting fluorescence emission in-
stead of non-radiative de-excitation. FAPs are easy to
genetically engineer and express as fusions to
proteins of interest. Biological targets in live cells can
be specifically visualized by addition of fluorogens
without need for washes because unbound fluoro-
gens do not fluoresce. Visualization of targets inside
cells [3,5], on the cell surface [3,7,9,15] or within
trafficking vesicles [8,11–13,16,17], can be selectively
controlled using membrane-permeant or impermeant
fluorogens.
Several apparent scFvs that respectively activate
several diverse methine dyes have been isolated
from a yeast surface display library that expresses
~109 recombinantly fused VHVL domains derived
from human spleen and lymph node cDNAs; small
subpopulations of single VH and VL domains are also
expressed. ScFv/methine dye complexes that fluo-
resce in near-UV [4,10], visible [3,4], and far-red
[3,4,7,14] spectral regions have been characterized.
In addition to enhancing fluorescence, binding tocognate scFvs modulates the excitation and emis-
sion maxima of these methine dyes, producing red
shifts of 5–60 nm relative to unbound dye.
Six proteins isolated from the library specifically
activate a pegylated derivative of malachite green
(MG). MG-binding FAPs enhance fluorescence by as
much as 20,000-fold relative to unbound dye to
brightness levels typical of fluorescent proteins and
emit in the far-red spectral region (~670 nm) where
cellular autofluorescence is low, making these fluor-
omodules well suited for further development. Al-
though isolated from a nominal scFv library, five of
these proteins function efficiently as a FAP when
expressed from only a single heavy or light variable
domain gene [3,6], but the stoichiometry and archi-
tecture of the functional FAP/MG complexes remain
unknown. To understand the three-dimensional struc-
ture of these unusual immunoprotein/ligand com-
plexes and the detailed mechanism by which MG
binds and fluoresces, we have determined their
crystallographic structures and studied their physical
and biochemical properties.
Here we report the structure and properties of a
spectrally improved FAP that carries a point mutation
acquired during affinity maturation of the progenitor L5
VL [3] (Fig. 1a and b). We study the properties of a
genetically fused tandemdimer of this VL and a tandem
dimer of a VL that carries a second mutation that
Table 1. L5 FAP nomenclature
Unique
identifier
Name in
this paper
Mutations
(Kabat)
Previously
published as
MBIC1 L5 WT L5-MG [4,6]
MG16 [11]
MBIC2 L5* L89S L5-MG L91S [6]
L5 L91S [5]
L5-MG L90S [3]
MBIC3 dL5* L89S
(VL/VL dimer)
MBIC4 L5** L89S E50D L5-MG L91S
E52D [6]
MBIC5 dL5** L89S E50D
(VL/VL dimer)
dNP138 [9]
4597Malachite Green Dimerizes Antibody VL Domainsimproves binding affinity (Fig. 1b). Figure 1a presents
the Kabat numbering of the relevant mutations, and
Table 1 lists the simplified nomenclature we use in this
paper, together with cross-references to previous
studies using some of these improved FAPs but
with different nomenclature. Improved versions of L5
fluoromodules have been applied to date in vivo to
stimulated emission depletion super-resolutionmicros-
copy [5], to a fluorescence resonance energy transfer
system that amplifies FAP signal [7], as the VL
component in hybrid VHVL sensors [6], as a sensor ofTable 2. X-ray data collection and refinement statistics
X-ray data collection L
Beamline SSRL
Wavelength (Å) 0.980
Resolution (Å) 1.93 (
Space group: a, b, c (Å) P41: 5
No. of observations 90,51
No. of unique reflections 21,28
Completeness (%) 99.8 (
Rsym (%) 5.4 (5
Average I/σ 23.3 (
Refinement statistics (all reflection N 0.0 F/σF)
Resolution (Å) 27.43
No. of reflections (working set) 21,25
No. of reflections (test set) 1094
Rwork (%) 19.3 (
Rfree (%) 23.1 (
Stereochemical parameters
Wilson B (Å2) 24.7
Average isotropic B: all atoms (Å2) 32.4
Average isotropic B: protein chains (Å2) A, B:
Average isotropic B: MG (Å2) N/A
Average isotropic B: waters (Å2) 39.0
No. of atoms (protein/water/glycerol/mannose/MG) 1649/
RMSD bond lengths (Å) 0.007
RMSD bond angles (°) 1.19
Ramachandran plot distribution from Procheck [81] 90.9%
8.0%
0.0%
1.1%
Rsym = Σ|Ii – 〈Ii〉|/Σ|Ii|, where Ii is the scaled intensity of the ith measur
Fobs| – |Fcalc||/Σ|Fobs|, where Fcalc and Fobs are the calculated and obse
but for 5.0% of the total reflections chosen at random and omitted fromprotein O-glycosylation [17], and to trafficking investi-
gations of anion [13] and cation [15] channels.
Crystallography shows that a single MG is bound
along a novel interface between two L5* VLs to form
a ternary complex where proteins and ligand share a
single C2 symmetry axis. Ternary complexes with
2:1 protein:ligand stoichiometry and inclusive C2
symmetry are very rare in nature (about 10 natural
complexes found in the PDB; see Table S1 and
Swapna et al. [18]). However, many C2-symmetric
ligands have been designed to inhibit the homo-
dimeric human immunodeficiency virus (HIV) prote-
ase (Table S1), and several C2-symmetric bivalent
ligands that mediate the assembly of protein homo-
dimers have been synthesized (so-called chemical
inducers of dimerization, CIDs [19,20]).
We describe in detail how the symmetric protein/
protein and protein/ligand interfaces of the L5*
complex differ from interfaces of unliganded VL/VL
homodimers associated with disease and from the
interfaces of canonical liganded VH/VL heterodimers.
We show that unliganded L5* exists primarily as a
monomer in solution, but addition of MG mediates
cooperative assembly into a stable ternary complex.
MG behaves as a CID, but it differs functionally from
current bivalent CIDs. A genetically fused dimer of5* unliganded L5* liganded
11-1 SSRL 11-1
1.040
1.96–1.93) 2.45 (2.49–2.45)
4.86, 54.86, 95.32 P43: 94.34, 94.34, 176.28
2 (4956) 213,775 (10,689)
7 (1086) 56,006 (2781)
99.7) 99.9 (100.0)
4.6) 7.3 (50.6)
3.1) 20.5 (2.4)
–1.93 (2.02) 34.18–2.45 (2.49)
9 (2522) 55,944 (2630)
(141) 2839 (149)
28.9) 19.4 (36.2)
33.6) 22.5 (38.7)
39.1
46.7
30.2, 33.6 A, B, C, D: 36.3, 40.7, 40.7, 36.5
E, F, G, H: 51.0, 59.7, 60.5, 49.0
I, J, K, L: 26.5, 25.2, 48.3, 44.3
42.3
141/0/11/0 6424/169/72/33/104
0.008
1.25
core
allowed
generously allowed
disallowed
90.1% core
8.8% allowed
0.0% generously allowed
1.1% disallowed
ement and 〈Ii〉 is the mean intensity for that reflection. Rcryst = Σ||
rved structure factor amplitudes, respectively. Rfree is as for Rcryst,
refinement.
4598 Malachite Green Dimerizes Antibody VL Domainsthe L5* protein and MG assemble as a binary
complex of much higher affinity. We discuss why
selection and directed evolution using a small
symmetric fluorogen as bait has produced these
novel fluorescent ternary and binary L5* complexes,
which hold promise as self-reporting CIDs and
affinity capture reagents.Fig. 2. Global structure of L5* homodimer. (a) Chemical
structure of MG fluorogen. MG diethylene glycol diamine
linker is truncated at O1 (arrow) in crystallographic
depictions. Red broken line marks C2 symmetry axis that
passes through O1, ring R1, and the central carbon.
Scheme depicts delocalized electronic structure consis-
tent with liganded L5* crystal data; the central carbon is
linked to rings R2 and R3 by equivalent partial double
bonds (1.44 Å) and to ring R1 by another partial double
bond (1.48 Å). (b) Main-chain views of liganded and
unliganded L5* homodimers. (Top) Frontal view toward
O1 along the coincident C2 symmetry axes of MG and the
homodimer. SAS representations (1.4 Å probe) of MG and
binding cavity boundaries are respectively shown in yellow
and transparent pink. Space-fill water molecules are
shown as blue spheres, and Cα carbons of N-terminal
(Val3, red) and C-terminal (Val106, green) VL residues are
shown to illustrate the antiparallel homodimer configura-
tion. (Bottom) Side view of homodimers, rotated 90°
leftward from those in top view. The liganded VL domains
are each rotated 10° toward the back of complex relative to
unliganded domains (arrows), increasing separation be-
tween N-termini by 2.6 Å.Results
The L5* FAP studied here is a leucine-to-serine
point mutant (Ser89) obtained by directed evolution of
L5, which is a VL single domain antibody fragment
selected from the original yeast display library (Fig. 1)
[3,21]. L5* derives from the human IGLV7-46 germline
λ allele; this progenitor allele appears to have
undergone immune somatic hypermutation, generat-
ing differences from germline-encoded amino acids at
6 positions scattered within the conserved framework
and at 12 positions within the CDRs, particularly
CDR2 and CDR3 (Fig. 1). L5* and its germline
progenitor are atypical λ genes and are members of
an outlier sequence population that comprises only
2% of the λ repertoire (Fig. S1).
L5* binds to MG to form a bright fluorescent
complex that improves on the quantum yield of the
original L5 FAP by about 5-fold (QY = 0.24) but does
not appreciably change other spectral properties or
apparent binding affinity [3]. This fluorescent com-
plex is comparable in brightness to commercially
available fluorescent proteins, such as EGFP and
mCherry [22], but emits in the far red.
Liganded and unliganded L5* VL domains
crystallize as highly symmetric homodimers
L5* protein at high concentration (~1 mg/ml)
migrates on a size-exclusion chromatography column
as a 28.7-kDa dimer in the presence of MG but, in its
absence, runs as a 14.2-kDa monomer with a small
shoulder in the dimer position (Fig. S2a), suggesting
that, in the absence of ligand, protein monomers are
only weakly attractive with an estimated dissociation
constant (Kd) of N200 μM. Glutaraldehyde treatment
in the presence or absence of MG inefficiently cross-
links VL monomers in solution to stabilize dimers but
not multimers (Fig. S2b).
Crystal structures of L5* were respectively deter-
mined at resolutions of 1.93 Å (unliganded) and
2.45 Å (liganded); crystallographic parameters are
summarized in Table 2. The crystallographic unit cell
for liganded L5* contains four very similar homo-
dimers (eight chains A–H that form the four A/B, C/D,
E/F, and G/H homodimers); for simplicity, the data
and analyses focus on one dimer composed of
chains A and B. The triarylmethane core of the
MG-2p-NH2 ligand (Fig. 2a) is well resolved, but the
flexible diethylene glycol linker is not ordered. This
Fig. 3. Comparison of VH/VL contacts and VL/VL
contacts of representative antibodies. Shown are inter-
domain contact surface areas as calculated on the SPACE
server, based on atoms of 4 Å or less separation. Graph
bar colors represent classes of paired CDR and framework
contacts that comprise the contact surface for each
antibody; gray and white backgrounds distinguish three
classes of contacts. CDRs are designated by Kabat
number, and the framework is designated “F”. For
simplicity, surface area shown for each paired contact
represents that interaction summed from both chains
(VL + VH or VL + VL). Parallel scFv or scFv-like configura-
tions are labeled in black, and antiparallel homodimer
configurations are labeled in red. Liganded (+) and
unliganded (−) complexes are shown for L5*. Complexes
A–C bind small molecules (listed by PDB ID): 2C1P,
anti-finrozole (drug); 3CFB, anti-trans-stilbene (dye);
1FLR, anti-fluorescein (dye). Complexes E–I are Bence-
Jones and related proteins: 1LVE, 1QAC (point mutant of
1LVE in flipped configuration), 2Q1E, 2RHE, and 1IVL;
these structures are compared to L5* in Fig. S3.
4599Malachite Green Dimerizes Antibody VL Domainssmall linker, which may be replaced by an ethyl ester
with minor effects on ligand affinity or fluorescence
[3], is therefore not included in our analysis.
Liganded and unliganded L5* form homodimeric
complexes in the crystal that are very similar in
overall structure (Fig. 2b). The homodimers assume
a 2-fold symmetric antiparallel configuration; each VL
contacts the other via an interface composed of
identical but 180° rotated VL surfaces. A cavity exists
between the VLs in both homodimers. In the liganded
complex, a single MG resides in the cavity, oriented
so that the proximal oxygen atom (O1) of the linker
points outward, roughly orthogonal to the homo-
dimer surface. MG and the homodimer share a
single C2 symmetry axis through the O1 atom of the
dye.
The peptide backbones of single liganded and
unliganded VLs superpose very closely, with an
average Cα RMSD of 0.51 Å (for Val3–Val106).
Local deviations between liganded and unliganded
VL main-chain frameworks are found within the
CDR3 loop, which, in the liganded complex, makes
extensive contacts with both MG and the other VL,
and within a non-CDR loop (residues 39–43) that
makes a contact with a neighboring VL dimer in the
asymmetric crystal unit (see below and Fig. S2c).
Although individual liganded and unliganded VLs are
highly similar in structure, liganded and unliganded
VL dimers differ in the relative orientation of their
constituent VL monomers; upon superposing one VL
from each dimer, the second liganded VL is rotated
by 20° relative to the second unliganded VL. This
change in relative orientation increases the separa-
tion between the liganded VL domains at the opening
of the binding cleft but slightly decreases separation
distal from the opening (Fig. 2b and Fig. S2c).
L5* and natural antibodies differ in organization
of CDRs along recognition interfaces
Full-length light chains can self-associate or aggre-
gate in myeloma (Bence-Jones proteins) and in light
chain amyloidosis diseases, sometimes as homo-
dimers that associate via the conserved interface that
is used in standard light chain–heavy chain Fab
heterodimers. Several light chain dimer variable
domains have been recombinantly expressed, and
these formVL/VL homodimers, usually in an assembly
similar to a Fab VLVH domain. However, crystal and
NMR structures have also revealed a variety of
non-Fab-like configurations, including antiparallel
homodimers similar to that of L5* [23,24]. We have
recently shown that conformers of an asymmetric
fluorogen (dimethylindole red) bind to an antiparallel
VL/VL homodimer, M8 [14]. We compare the struc-
tures of L5*, M8, and these disease-related homo-
dimers in Fig. S3a. In conventional antibodies, ligand
binding is primarily mediated by CDRs, whose
sequence and structure are modified to this purposeduring the immune response, whereas the framework
regions thatmediate domain interactions are relatively
conserved. Because the VL/VL interface is rearranged
in the L5* homodimer that binds ligand, we analyzed
the domain/domain contacts made by CDR and
framework residues for L5*, M8, disease-related
VL/VL homodimers, and typical small-molecule-
binding VHVL heterodimers (Fig. 3 and Fig. S3b).
Domain/domain contacts of L5* differ extensively
from those of classical VLVH heterodimers. In a
typical heterodimer, framework/framework contacts
comprise almost half of the interacting surface. In the
L5* homodimer, framework/framework contacts
comprise only about 5% of that surface, namely, a
single Phe49/Phe49 contact in the liganded complex
(Fig. S4). Instead, CDR/CDR and CDR/framework
contacts assume an expanded presence, especially
those involving CDR3, which participates in almost
three quarters of contacts seen in unliganded L5*
(Fig. 3). Almost all CDR3 interdomain contacts are
made to framework residues, whereas CDR1 and
CDR2 make significant interdomain contacts to
framework residues and with each other. The
domain interface of the M8 homodimer is notably
smaller and is comprised almost entirely of CDR3/
4600 Malachite Green Dimerizes Antibody VL Domainsframework and CDR1/framework contacts. In Fab
heterodimers, CDRs also contact one another across
the light/heavy interface, but the three predominant
pairwise interactions differ from the CDR1/CDR2
contact made in L5*. Most VL/VL homodimers have
interdomain contacts similar to those of the hetero-
dimers (Fig. 3). Compared to L5*, VL/VL structures that
have rotated domains retain significantly more frame-
work/framework contacts,make somewhat lesser use
of CDR3-mediated contacts, andmake different CDR/
CDR contacts (Fig. 3).
To explore ligand binding architecture, we com-
pared the liganded structures of L5* and a classical
4-4-20 monoclonal antibody that binds fluorescein,
which in scFv format has beenmatured to femtomolar
affinity with little change in structure [25–28] (PDB ID:
1FLR) (Fig. 4a). The VL and VH of 4-4-20 assume a
nearly orthogonal orientation rather than the antipar-
allel orientation assumed by L5* VLs. MG is located
near the center of mass of the L5* complex, not in the
canonical antigen binding site as in VLVH complexes
such as 4-4-20. MG and fluorescein contact respec-
tive VLs at different positions and in different orienta-
tions, reflecting a general rearrangement of the
classical binding apparatus.Fig. 4. Variable region architecture of the L5* homodimer an
make different contacts and bind ligand at different posi
(anti-fluorescein 4-4-20) were superposed to illustrate relativ
positions of full VL/VL or Fab (VH/VL) complexes are shown by r
as red broken line. (b) L5* and antibody 1FLR have a different r
dimers. Ribbon and SAS renderings of liganded L5* and 1FLR
(front) and from the opposite side (back, after vertical rotation
residues are colored as indicated.The VL and VH backbones establish a roughly
circular framework for the sixCDR loops that comprise
the binding site of a classical antibody. For antibodies
that bind small molecules, this site is usually a fairly
deep cleft that maximizes CDR contacts with the
ligand yet is open at one end to facilitate the binding
event (Fig. 4b). By contrast, the CDRs that, in part,
comprise the L5* binding site are symmetrically
distributed along the intricate interface between VL
domains and support both domain/domain and
domain/ligand contacts (Figs. 4b and 5a).
A highly structured binding cavity encapsulates
the ligand
Unlike small ligands that can freely access VLVH
binding clefts, MG is entrapped within a cavity where
the single opening is far too small to permit direct
ligand passage. CDR3 partly brackets this opening
and flanks the front part of the cavity, whereas CDR1
and CDR2 flank the rear of the cavity (Fig. 5a) and
comprise part of the back surface of the VL/VL
complex (Fig. 4b). Although it also has an antiparallel
architecture, the M8 homodimer has a very different
binding pocket configuration—an elongated cleftd a classical antibody. (a) L5* and 1FLR variable domains
tions and orientation. VL domain from L5* and 1FLR
e orientations of their cognate domains. Mass centroid
ed dots in the VL-only depictions; the L5* C2 axis is shown
elative spatial arrangement of their CDRs in the VL and Fab
complexes are shown looking toward the binding pocket
). In SAS renderings, ligands, CDR, and framework (FR)
Fig. 5. Structural features of the L5* MG-binding cavity. (a) Movement of Tyr96 on CDR3 accommodates binding of MG.
Cut-away SAS renderings of liganded and unliganded complexes show VL with highlighted CDRs, plus CDR1 and CDR3
of partner VL (*); waters are shown as space-fill spheres. Red mesh highlights the labile Tyr96 side chains that rotate to
clasp the R1 phenyl ring of bound MG; red broken line shows C2 symmetry axis. (b) MG binding induces CDR3
deformation. Superposed Cα backbones are shown with CDRs and the amino acid 39-43 loop outside of binding region
highlighted as indicated for both liganded and unliganded domains. The respective CDR3 Tyr96 side chains (cyan) are
shown in the context of the bound space-filling representation of MG (yellow). The disulfide bond that links Cys88 at the
base of CDR3 to Cys22 at the base of CDR2 is shown in cyan. (c) Arrangement of MG and water in binding cavities. Top
view of SAS rendered MG (yellow) and cavities (pink) and space-fill waters (blue) show positions relative to VL backbones
and C2 axis. The liganded cavity is subdivided into two contiguous compartments. Cavities were calculated using Hollow
software with a 1.4-Å probe (water diameter) [29]. (d) MG binding may disrupt a hydrogen bond network. Shown are ribbon
cartoons of liganded and unliganded VLs with all side chains that make major contacts with MG. Hydrogen bonds between
Tyr96, Ser89, and Asn34 side chains are shown as black broken lines in unliganded VL.
4601Malachite Green Dimerizes Antibody VL Domainswith a broad opening near CDR2 that accommo-
dates both dimethylindole red conformers (Fig. S3a).
The most conspicuous feature of the L5 binding
cavity is the conformational change that accompanies
binding of ligand. The CDR3 Tyr96 side chain points
outwards from the liganded pocket but inwards to the
empty pocket, overlapping into space otherwise
occupied by MG (Fig. 5a and b and Fig. S5a).
Together with the framework Phe98 side chain, the
Tyr96 side chain forms a clasp that embraces the R1
ring of MG and hinders direct dissociation of MG from
the assembled ternary complex. These stereochem-
ical obstacles would be fixed in place by accompany-
ing MG/VL and VL/VL interactions, thus constituting
a kinetic trap that cooperatively stabilizes the full
complex.MG and internal waters are almost completely
encapsulated inside a 690 Å3 cavity (Fig. 5c) that
is divided into two contiguous subspaces between
which water-sized molecules cannot exchange
without conformational dynamics (Fig. S5b). MG
resides within a 580 Å3 subspace that approxi-
mates the shape of the ligand and is over twice its
volume (260 Å3) [29] but does not contain struc-
tured waters (Fig. 5c and Fig. S5b). A 110 Å3
subspace abuts the rear of MG rings R2 and R3 and
contains a symmetrically distributed cluster of 5
structured waters, 3 waters in the plane of MG and
single waters above and below (Figs. 2b and 5a and
c; Fig. S5b). Each of the 5 waters makes at least one
hydrogen bond to an amino acid in van der Waals
contact with MG (Asn34 and Tyr55) (Table S2 and
4602 Malachite Green Dimerizes Antibody VL DomainsFig. S4). These features fit the generalization
that binding pockets are on average 3-fold larger
than their ligand and may have a free space “buffer
zone” often occupied by water [30], especially
if polar side chains are available for hydrogen
bonding [31].
Unliganded dimer displays a symmetrical 405 Å3
cavity partly filled with 9 resolved waters that make
hydrogen bonds to 14 protein interface atoms, 8 of
which make van der Waals contact with MG in the
liganded complex (Figs. 2b and 5a and c; Fig. S5b and
Table S2). The distribution of waters within the
widened cavity suggests the potential for binding 13
structured waters. The Tyr96 that forms the cavity
front side is hydrogen bonded to Ser89 on CDR3, and
Ser89 is also hydrogen bonded to Asn34 on CDR1
(Fig. 5d). The side chain of each of these residues
rotates to make significant contacts with MG in theFig. 6. MG interactions with L5*. (a) Atom-level spatial symm
MG and associated water molecules. Figure represents a coord
(blue) overlaid onto the second VL domain with bound MG a
domain were directly superposed (shown as gray traces); this a
(RMSD, 0.30 Å), MG (RMSD, 0.35 Å), and 5 internal wate
conserved spatial locations relative to the VL. (b) Spatial distribu
contacting side chains from both VL A (black letters) and VL B
locations and orientations. (c) MG atomic contacts made to
non-hydrogen atom position represents total surface area of con
in light blue and contacts to VL B are shown in orange. Major co
(d) MG binds L5* and an RNA aptamer [33] as left-handed and r
axis of L5 * (yellow) and aptamer (purple) ligands superposed v
superposed via the triarylmethane plane defined by carbon atliganded complex; if this intradomain hydrogen bond
network exists in solution, its disruption—presumably
by direct contact with the ligand—would be a
prerequisite to binding.
Symmetrical interactions between MG conformer
and VL domains
BoundMGandstructuredwatersmake contactswith
the VL domains that are symmetric at the atom level
(Fig. 6a). The geometry of MG is not related to the
spatial distribution of amino acid contacts in a simple
way—there is no “face” or “end” of MG that is
recognized by each interdigitated VL domain (Fig. 6b
and c). VL-to-MG bonds occur as pairs, from corre-
sponding atoms on each VL to corresponding atoms
(or a single atom) onMG that are 2-fold symmetric with
respect to MG geometry.etry of ligand contacting amino acid side chains relative to
inate set of one VL domain with boundMG and the 5 waters
nd waters (yellow). Only backbone α-carbons of each VL
lso results in superpositioning of the amino acid side chains
rs (shown near Asn34; RMSD, 0.29 Å), demonstrating
tion of amino acid side chains that contact MG. Shown are
(red letters) that comprise a set of pairwise symmetrical
L5* are symmetrical and complex. Size of circle at each
tacts to L5* made by that atom; contacts to VL A are shown
ntacts made by the dimethylamine carbons are marked (*).
ight-handed propeller conformers. Top, front view alongC2
ia Ring 1. Bottom, front view along C2 axis of these ligands
oms 2, 8, and 14 [see (c)].
Table 3. Amino acids that bind MG also mediate direct VL/VL contacts
Amino acid Location Unliganded L5*
VL/VL contacts (Å
2)
Liganded L5*
VL/VL contacts (Å
2)
Liganded L5*
VL/MG contacts (Å
2)
Y32 CDR1 104.2 204.7 37.2
N34 CDR1 0 23.3 48.2
F36 FR 77.8 62.4 86.2
A46 FR 62.6 40.9 11.2
Y55 CDR2 66.4 110.1 86.4
S89 CDR3 0 0 95.8
S91 CDR3 57.4 73 76.9
Y96 CDR3 208.6 190.4 87.5
F98 FR 25.1 10.1 42.9
MG contacting: total 714.9
L5* complex: total 875.8 964.2 575.7
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exclusively van der Waals. Contacts with CDR atoms
tend to occur along the edge of the triarylmethane
plane, and contactswith framework atomsoccur above
and below this plane (Fig. 6b). Five of nine contacting
amino acids are aromatic. Aromatic side-chain rings
are inclined at various high angles to the triarylmethane
rings; none of these side chains are positioned so as to
promote π/π or π/σ stacking interactions.
The closest contacts with MG are made by Ser89
and Ser91, located near the base of CDR3. MG
methyl carbons become wedged into a slot that is
formed by Tyr96 side-chain rotation upon binding of
the ligand (Fig. S5c); these 4 carbons account for
about half of the total MG/VL contact area (Fig. 6c).
The Ser89 point mutant enhances the fluorescence
quantum yield 5-fold by replacing an aliphatic
leucine with the smaller polar serine; the smaller
side chain may promote better constraint of the
bound chromophore by facilitating more extensive
contacts with the dimethylamine carbons.
Over 90% of the MG solvent-accessible surface
(SAS) is buried upon binding (576 Å2 total)
(Table 3). Eight of nine residues that significantly
contact MG also make simultaneous contact with the
other VL; these amino acids, especially three
tyrosines, account for 715 of 964 Å2 of SAS that is
buried by direct VL/VL contact in the liganded
complex. Binding of MG increases overall VL/VL
contacts significantly, with especially large increases
for Tyr32 on CDR1 and Tyr55 on CDR2 (Table 3 and
Fig. S4).
In addition to providing direct bridging contacts,
the binding of MG may promote conformational
changes involved in assembly of the L5* homodimer.
In particular, the CDR3 backbone conformation is
altered upon binding MG so that CDR3 interdomain
contacts are slightly reduced in the liganded
complex (Fig. 5b and Fig. S4). Conformational strain
induced by the binding of MG, as reported for other
protein/small-molecule ligand systems [32], likely
deforms the CDR3 backbone; excluding CDR3 and
the 39-43 loop (Fig. S2c), the remaining 90 residues
constitute a nearly invariant main-chain framework(Cα RMSD of 0.27 Å). The binding of MG and
changes in CDR3 conformation are also associated
with repositioning of CDR1 and CDR2, reducing the
cavity size at the rear of the ternary complex (Fig. 1b
and Fig. S5a). The overall protein/protein contact
area increases significantly in three pairs of contacts
mediated by these CDRs, most prominently via
interdomain contacts between CDR1 and CDR2
(Fig. 3 and Figs. S4 and S5a).
Each of the MG rings is rotated to an angle
that optimizes bonding contacts with symmetrically
located VL atoms. Perfect 2-fold symmetry would
dictate that rings R2 and R3 have the same rotation
handedness and the same rotation angles. MG binds
to L5* homodimer as a left-handed propeller with
somewhat variable rotation angles found in the
crystallographic asymmetric unit, averaging 41° for
ring R1 and 32° and 30° for rings R2 and R3 (Fig. 6d
and Fig. S6). A well-studied RNA aptamer binds MG
as a right-handed propeller with rotation angles of 74°
for ring R1 and 26° for rings R2 and R3 [33] (Fig. 6d);
this aptamer/dye complex (quantum yield, 0.19) is
slightly less fluorescent than the L5* fluoromodule [34]
(quantum yield, 0.24). These propellers differ from
the minimum energy conformation of free dye, which
is not a propeller (Fig. S6b).
MG displays two absorbance (excitation) bands, a
main (X) band contributed by rings R2 and R3 and a
minor (Y) band contributed by ring R1. A relatively
large amplitude and a bathochromic (red) shift of the
Y band is predicted for cases where the R1 ring is
minimally rotated out of the R2–R3 plane [35];
indeed, the L5*/MG complex displays a Y absor-
bance band at 480 nm with a 1.5-fold greater
amplitude relative to the 455-nm Y band of free
MG in solution (Fig. 8a) [3], consistent with increased
coplanarity of the three phenyl rings of the dye.
Spectral and thermodynamic evidence for
MG-mediated assembly of a stable ternary complex
When we initiated this work, we observed that this
single domain FAP underwent unusually slow
fluorescence activation if mixed with MG in vitro;
Fig. 7. Paths for assembly of VL/MG/VL complex. Shown
are binding equilibria for the formation of ternary complex via
protein/ligand (a) or protein/protein (b) intermediates.
4604 Malachite Green Dimerizes Antibody VL Domainsactivation rates increased with higher protein
concentration. We interpreted this result as evidence
of formation of protein multimers, likely as dimers
in a ternary or quaternary complex with dye. This
crystal structure clearly shows the presence of a
ternary complex. Assembly of a VL/MG/VL ternary
complex via two equilibrium steps may occur via
either of two paths as shown in Fig. 7. These two
assembly paths cannot be easily distinguished by
fluorescence assay if the intermediate complex
cannot be detected because VL/VL or VL/MG is
short-lived or poorly fluorescent. At the concentra-
tions of VL (10–250 nM) that allow us to monitor
the kinetics of ternary complex formation using
fluorescence as an endpoint assay, we are unable
to directly detect either of these intermediate
complexes. We are developing an analysis using
fluorescence activation kinetics to establish rates for
each of these assembly paths, which will be
published elsewhere.
We sought to bolster spectral and thermodynamic
analysis by constructing a covalent VLVL homodimer
(dL5*) designed to function as a unitary VLVL protein
that is fluorescently activated by binding a single
MG. dL5* is coupled by an extended (GGGGS)4
linker sufficiently long to accommodate the antipar-
allel architecture without the formation of intermole-
cular dimers of dimers [36], and the upstream
domain is codon optimized to suppress recombina-
tion (Fig. S7a). We also built a similar covalent
homodimer (dL5**) carrying a second point mutation
(Asp50) in each VL domain (Fig. 1b and Fig. S7a) [7];
when expressed as a monomer putatively assem-
bled into ternary complex with MG dye, this double
mutation confers tighter binding while maintaining
increased brightness.
The fluorescence spectra of the L5* monomer
assembly and the dL5* dimer are essentially
indistinguishable (excitation max, 634 nm; emission
max, 667 nm) (Fig. 8a). Quantum yields for L5* and
dL5* are the same within error (0.24) and slightly less
for dL5** (0.20). To confirm that the fluorescent
species is the dimer, we used fluorescence correla-
tion spectroscopy to compare L5* and the dL5* and
dL5** constructs. At low MG concentrations (4 nM)
where protein monomer is in large excess (10 μM),
we observed signal only from L5* species of thesame hydrodynamic radius as dL5* and dL5**
(Fig. S7b). This experiment also suggests that,
under these conditions, fluorescent higher multimers
or aggregates are not readily formed.
Using fluorescence as a proxy for assembly of
protein/dye complex, we measured the affinity of MG
binding to dL5* by equilibrium assay (Fig. 8b) and
binding to dL5** by on-and-off rates, obtaining
respective Kd values of 90 pM and 18 pM. We also
obtained a protein concentration-dependent “mac-
roscopic equilibrium” constant for formation of the
L5* ternary complex (Kd,obs = 140 nM using 300 nM
monomer) by analyzing experimental data as if only
a single equilibrium step were involved. While not
informative on underlying mechanism, this empirical
binding parameter is experimentally useful.
A method for the exact analysis of equilibria has
been published for protein homodimerization medi-
ated by a homobifunctional ligand [37], a special
case of path (a) for ternary complex assembly
described above. Because MG has 2-fold symmetry,
we analyzed equilibria for the binding of MG to L5* to
ask whether MG behaves as a homobifunctional
ligand. In this scenario, MG reversibly binds L5* to
form a VL/MG pre-complex, which may then revers-
ibly bind another VL to form the VL/MG/VL complex.
This second step affords the opportunity for protein/
protein or altered ligand/protein interactions that may
enhance or inhibit binding so that formation of the
ternary complex becomes positively or negatively
cooperative. The exact algorithm [37] is expressed in
terms of the monovalent dissociation constant Kd for
the binding of dye to protein monomer. Equilibria for
the assembly steps include stoichiometric coeffi-
cients due to dye bivalence and incorporate a
binding cooperativity factor (α): (i) Kd′ = (1/2)Kd and
(ii) Kd″ = 2Kd(1/α). The thermodynamic model pre-
dicts that Kd values will depend on protein concen-
tration and that ternary complex will be competitively
dissociated by a large excess of ligand. Our
equilibrium experiments at different protein concen-
trations show complete assembly into ternary
complex but without significant dissociation at very
high concentrations of ligand, thus giving direct
evidence of strong positive cooperativity (Fig. 8c).
For reasonable values of binding affinity and
cooperativity (Kd = 50 μM, α = 2 × 10
5), the exact
analysis computation algorithm approximates our
experimental titrations at low protein (b50 nM) and
ligand (b1 μM) concentration but underestimates the
extent of ternary complex formation at high ligand
concentration. Better but still partial fits to experi-
ment are obtained using much higher Kd and α
values. These data suggest that MG-mediated L5*
dimerization involves mechanisms different from
homodimerization mediated by an “ideal” homobi-
functional ligand that binds separate identical sites.
In this case, kinetic trapping of encapsulated ligand
could make dissociation of the complex insensitive
Fig. 8. Characterization of L5*/MG complex formation. (a) Normalized fluorescence of L5* ternary complex and dL5*
binary complex. Main (X) and ancillary (Y) excitation bands are marked. (b) Equilibria of dL5* binary complex. Plot shows
proportion of 150 pM dimer protein assembled into a binary complex as a function of MG concentration. Ligand depletion
analysis gives a KD of 90 pM. (c) Equilibria of L5* ternary complexes. Plot of experimental data shows proportion of total
VL assembled into VL/MG/VL ternary complex (θV
VMV) as a function of MG concentration employing indicated initial
VL concentrations ([V]0, continuous lines). Data are corrected for inner filter effect. Full assembly occurs over MG range of
25–200 μM for all initial VL concentrations (linear plot of [MG], inset). Computed values [37] of the proportion of monomer
assembled into complex are shown for indicated VL concentrations [V]0 using Kd = 50 μM and cooperativity parameter
α = 2 × 105 (broken lines) or Kd = 1200 μM and α = 1 × 10
8 (dotted lines). The shown equation predicts the maximum
extent of ternary complex formation (θV
VMV
max) as a function of these two variables [37]. (d) Isothermal titration calorimetry
of L5* and dL5*. Listed thermodynamic parameters of dL5* (kJ/mol) are derived from these ΔH values and the
experimentally determined Kd value in (b).
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ligand.
Given that the binding of MG appears to cooper-
atively drive formation of the ternary complex from
monomeric precursors, it was of interest to examine
the energetic contribution of MG to these assembly
processes. We thus carried out isothermal titration
calorimetry on formation of L5* and dL5* complexes
(Fig. 8d). The enthalpy of MG binding to form both of
these complexes is substantial and roughly equal
(ΔH = −67 to −71 kJ/mol). Using the ΔG value from
the equilibrium binding experiment with dL5*, it can
be seen that binding to the dimer is driven entirely by
change in enthalpy; the small negative change in
entropy works against binding. MG binds dL5* much
more tightly than almost all small-molecule biological
ligands bind cognate proteins; MG/dL5* bindingaffinity is typical of certain very tight binding
medicinal ligands, in particular, several inhibitors
of HIV protease and gyrase B, but with a larger
enthalpy contribution [38] (Fig. S8).
The enthalpy data suggest that the assembly of
L5* and dL5* fluorescent complexes involves the
formation of similar sets of specific van der Waals
interactions with MG [39,40]. The indistinguishable
fluorescence quantum yields and spectra of L5* and
dL5* complexes (Fig. 8a) support this interpretation
because other MG-binding FAPs with unrelated
binding pockets have their own characteristic fluo-
rescence properties [3]. Efficient fluorescence acti-
vation of dL5* by 1500-fold lower concentrations of
MG is thus likely due to rotational and translational
constraints on movements of the coupled protein
monomers [32] and suggests that monomers fused
4606 Malachite Green Dimerizes Antibody VL Domainsto proteins of interest may sensitively report dimer-
ization or conformational changes of those proteins,
a property potentially useful for sensors.
The much tighter binding conferred by the covalent
linkage of L5* is potentially important for in vivo
applications. Using fluorescence microscopy and
fluorescence activated cell sorting (FACS), we
assessed the signal-to-noise properties of yeast cells
displaying our tightest binding FAP, dL5**, over a
10,000-fold range of MG concentrations (10 pM to
100 nM) (Fig. 9). The use of low concentrations of MG
in cell culture and in circulation in animals is desirable toFig. 9. VLVL dimer improves signal-to-noise and sensi-
tivity. (a) Confocal microscopy of dL5** displayed on yeast
surface. Yeast cells expressing dL5** encoded by single
copy chromosomal integrant were imaged on Zeiss
LSM510 laser confocal microscope with identical instru-
ment settings using 10–100,000 pM MG. To facilitate
viewing, we adjusted image contrast using Zeiss software
and inverted grayscale image. A representative quantita-
tion is shown in Fig. S9. (b) Flow cytometry quantitation of
dL5** displayed on yeast. Plot shows mean fluorescence
values (640 nm excitation) of cells treated with MG over
the indicated concentration range. Cellular autofluores-
cence in the absence of dye is about 6.reduce cytotoxicity and background fluorescence and
to facilitate experiments that would employ higher
concentrations of MG derivatives as chase reagents
[7]. Our data indicate that useful signal can be obtained
overMGconcentrations that range from100-fold below
to 100-fold above a saturating concentration of ~1 nM.
Signal-to-noise properties at very low MG concentra-
tions are sensitive to dye loss via competitive binding to
surfaces and to presumed non-fluorogenic sequestra-
tion of dyeby the vast excess of non-FAPbiomolecules
present in living systems.Discussion
The structure and behavior of the L5*/MG complex
and natural protein/ligand complexes diverge consid-
erably. Several roughly antiparallel structures of VL
homodimers from Bence-Jones proteins (Fig. S3a)
differ significantly from L5* in respect to VL/VL
contacts, primarily because of variations in transla-
tional and rotational displacement between mono-
mers. Bence-Jones proteins have no recognized
biological function or antigen but were an early
model system to study the reconstituted binding of
small organic molecules and peptides [41], which are
not known to mediate VL/VL homodimerization. Point
mutations can convert parallel scFv-like Bence-Jones
homodimers into low-affinity antiparallel configura-
tions [23,24], suggesting that some VL surfaces may
be especially amenable to mediating such rearrange-
ments of quaternary structure. Comparison of the L5*
structure to known human λ VL structures suggests
that eight framework amino acids located primarily
between CDR1 and CDR2 may be important for the
propensity of L5* to homodimerize rather than form a
canonical VL/VH heterodimer; six of these amino acids
diverge from the λ family consensus (Fig. S3b).
A small symmetric and conformable ligand that
mediates highly cooperative assembly
TheMG ligand has atom-levelC2 symmetry and can
bind as a conformable propeller to maximize interac-
tions between identical monomer surfaces. MG also
hasa large surfacearea (26non-hydrogenatoms),well
above the 15 atoms threshold that correlates with
typical maximal affinities of protein/organic ligand
complexes [42]. The MG/VL interface and VL/VL
interface together provide sufficient buried SAS
(1540 Å2) to support assembly of a stable ternary
complex. The buried VL/VL SAS (876 Å
2) of unli-
ganded L5* falls within a range (b1000 Å2) where
weak homodimerization predominates so that an
equilibrium mixture of monomers and dimers likely
exists in solution [43]. The hydrophobic interaction
energy (calculated using 49 ± 5 J mol−1 Å−2) [38]
estimated from the increase in buried SAS between
free L5* monomers and liganded homodimers
4607Malachite Green Dimerizes Antibody VL Domains(1540 Å2, ~75 kJ/mol) approximates our calorimetry
energetics, whereas the interaction energy of the
transition from unliganded to liganded homodimers is
much less (665 Å2, ~33 kJ/mol). These consider-
ations suggest that low micromolar solutions of L5*
are comprised almost entirely of monomer and that
the VL/VL interface in unliganded dL5* remains largely
solvent accessible.
The high degree of binding cooperativity in forming
the L5* ternary complex likely reflects the ability of MG
to make interdomain bridging contacts with VL side
chains, while simultaneously retaining and enhancing
direct VL/VL contacts mediated by these same side
chains. Thismay bea rare circumstance. The relevant
VL residues include large aromatic side chains that
maximize conformational adaptability of protein sur-
faces and neutral apolar side chains that adapt well to
changes in solvent exposure [44]. The rotational
flexibility of MG facilitates making energetically
favorable contactswith side chains lining the spacious
symmetrical pocket, which also harbors waters able to
provide configurable bridging hydrogen bonds. These
waters also may reduce solvent entropy changes that
accompany MG binding [45,46].
Encapsulation of MG between VL domains creates
a kinetic trap that stabilizes the ternary complex and
enhances cooperativity because release of ligand
requires the prior dissociation of a VL domain [47].
The VL/MG/VL tertiary binding interaction is much
stronger than any pairwise interaction among the
three components, and thus, pairwise dissociation
reactions are suppressed, in analogy to many
multi-subunit protein complexes [47].
Ternary complexes assembled by CIDs such as
the heterodimerizer rapamycin [48] and analogs, as
well as homodimerizers such as FK1012 [49] and
bis-methotrexate [50], have a fundamentally differ-
ent organization than the L5* ternary complex. Such
CIDs are true bivalent ligands composed of two
spatially separate moieties that tether protein domains
by binding to natural pockets exclusive to eachdomain.
These CIDs are much larger (900–1500 Da) than core
MG (345 Da), and the SAS buried within each of the
two liganded pockets (515–660 Å2) is comparable
to the total SAS buried by the interfacial contacts
that MGmakes with both VLs (575 Å
2). CIDs employ
two independent binding pockets to mediate assem-
bly of ternary complexes, whereas MG employs a
single interfacial pocket to mediate such assembly.
The entwinement of ligand binding and protein/protein
interaction functionalities is consistent with strong
cooperative assembly of the L5* ternary complex,
whereas in CID systems, steric modulation of the
relatively limited protein/protein interface affects li-
gand binding at the independent high-affinity sites to a
more limited extent [20].
Unlike L5* and chemically induced ternary com-
plexes, HIV protease exists as a stable homodimer
in the absence of ligand. In nature, several distinctviral polyprotein segments bind at the homodimer
interface along a cleft that is opened and closed by
two flexible “flaps”, and many symmetric and
asymmetric protease inhibitors have been rationally
fitted to block this labile binding site. Among the over
200 X-ray structures of liganded protease dimer are
many containing symmetric inhibitors bound as
single three-dimensional conformers that make
C2-symmetric contacts. Symmetric protease inhibi-
tors are larger (average 700 Da, Table S1) than the
MG core, yet the best inhibitors (which are asym-
metric) bind no more tightly than MG (Fig. S8).
MG binds to dL5* with an exceptional ligand
efficiency (2.3 kJ/mol non-hydrogen atom), using an
empirical ligand size scaling metric (FQ = 1.04 where
1.0 is optimal), suggesting that binding interactions
are more optimized than for nearly all small organic
molecule/protein interactions [51]. Ligand efficiency
generally correlates with burial of ligand SAS, but the
SAS of totally encapsulated MG ligand is too small to
account for its exceptional relative efficiency [51]. The
binding of MG promotes VL/VL dimerization by direct
van der Waals contacts but also may promote
dimerization via the formation of adjacent water-
mediated hydrogen bond bridges and, possibly, via
changes elsewhere along the VL/VL interface.
Changes in VL/MG/VL contacts and VL/VL contacts
may thus contribute to the high observed binding
enthalpy and ligand efficiency. Similar binding func-
tionalities may exist for the small ligand caffeine that
efficiently mediates the high enthalpy assembly of two
VHH domains into a ternary complex of unknown
structure [52].
Directed evolution using fluorogens to create
symmetric high-affinity ternary complexes
L5* protein was isolated and matured for improved
affinity and fluorescence using recombinant DNA
methods; the outcome is an atom-level symmetric
complex composed of unnaturally configured immu-
noproteins bound to an unnatural bait ligand.
Generation of fluorescence provides an exquisitely
sensitive screen for constraint of fluorogenic ligands,
which as applied here directly isolates MG-binding
FAPs that constrain all three rotatable chromophore
bonds. L5* demonstrates that molecular evolution
under highly selective pressures for geometry and
molecular constraint can produce protein/ligand
complexes with novel high-affinity interactions.
Disruption of framework/framework interactions that
define the canonical VH/VL orientation potentiates
ligand-mediated selection of stable alternate protein
structures (Fig. S3b). In this instance, the geometry
of the bait ligand is a determinant of the geometry of
the selected complex. This relationship strongly
contrasts with small molecules rationally designed
to bind at natural homodimer interfaces, as exem-
plified by HIV protease inhibitors.
1 http://www.bioinf.org.uk/abysis/
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symmetry axes for both protein dimer and ligand
such that amino acids that comprise crucial protein/
protein and protein/ligand contacts occur as mirrored
duplicates. Monod et al. and Goodsell et al. proposed
that the inherent cooperativity in forming and stabiliz-
ing C2 protein homodimers provides evolutionary
pressure that selects for advantageous mutations,
which always occur in duplicate [53,54]. We suggest
that L5* structure and behavior fits this paradigm with
respect to directed molecular evolution because
selection is for a fluorescent homodimer but extends
the paradigm to include a symmetric ligand at the
homodimer interface so that protein residues involved
in mirrored protein/ligand contacts become subject to
the same evolutionary pressures. The strongly se-
lected fluorogenic phenotype conferred by the muta-
tion to Ser89, which extensively contacts MG (Fig. 1a
and Figs. S4 and S5c), may be an example of
symmetry-enhanced molecular evolution. Yeast-dis-
played L5* comprises a tractable model system for a
more thorough exploration of these ideas.
It is striking that functional L5* ternary complex
appears on the yeast surface when VL domains are
expressed as AGA2p-VL fusion proteins because
the architecture of the display scaffold, composed of
AGA1p linked by two closely spaced disulfides to a
single AGA2p-VL, does not account for VL homo-
dimerization. We have directly fused L5* and dL5* to
another yeast display scaffold (SAG1p) [55] and
mutated two cysteines on AGA1p that comprise a
separate disulfide motif for potential linkage to a
second AGA2p-VL [56], without changing the relative
expression levels of L5* and dL5*. Using a pulse
chase strategy that selectively labels L5* ternary
complex inside cells, we have observed preferential
labeling of AGA1p-AGA2p-VL on budding daughter
cells, the primary region for de novo synthesis of cell
wall to which display scaffolds are covalently bound
(C.S.G., unpublished results). These observations
suggest, but do not prove, that AGA2p-VL fusion
peptide may be self-associating within the yeast
secretory apparatus, as has been reported for a
non-covalent MHC class II heterodimer [57]. AGA2p
is reported to self-associate at high concentrations
in vitro [58].
The greatly increased binding affinity conferred by
genetic fusion of VL monomers appears largely due to
reduced loss of entropy rather than changes in
chemical bonding. The large effect of constraining
the dissociation of monomers accords with the key
role they play in encapsulating the ligand. These
independent mechanisms of generating affinity sug-
gest that monomers may be mutated to improve
chemical bonding and that affinity improvements can
subsequently be captured and enhanced by linking
the monomers together.
Wehave fused affinity-maturedmonomers to create
dL5**, which is capable of rapidly binding MG with18 pM affinity. Because a MG-polyethylene glycol
conjugate was used to select L5*, polymer coupled to
MG does not interfere with binding of this ligand. A
second ligand such as biotin may thus be coupled to
the polymer to create an efficient non-covalent
capture or coupling reagent that reports the binding
event by fluorescence. dL5** differs from the strepta-
vidin-biotin system in that dL5** protein is a small
monovalent binder amenable to genetic fusion, and
MG is not present in vivo [59].
The ability of low concentrations of MG to efficiently
bind to low concentrations of the coupled form of L5*
(dL5*), but not to dissociated L5*, suggests that L5*
can be fused to biological target proteins to selectively
visualize them when homodimerized or polymerized
[5]. L5* can be stably expressed in vivo and self-
associate to generate useful fluorescence signal
[3,5–7,15,17]. Because the ternary complex is highly
stable, proteins that form transient homodimeric or
multimeric associations (e.g., receptors, enzymes,
and transcription complexes) can be kinetically
captured and, in some cases, accumulated as a
selectively visualized complex. Visualized complexes
stabilized by these means may also confer useful
cellular phenotypes, much in the manner of current
CIDs.Materials and methods
Modification and purification of protein
All in vitro experiments, FACS selection, and microscopy
were carried out in PBS+ buffer [1× phosphate-buffered
saline (PBS), 2 mM ethylenediaminetetraacetic acid, and
0.1% (w/v) Pluronic F127 (pH 7.4)]. The progenitor L5-MG
clonedescribed inSzent-Gyorgyiet al. [3] was subjected toa
single round of random mutagenesis PCR based on the
mutagenic nucleotide analogs 8-oxo-dGTP and dPTP [60].
DNA from six parallel error-prone PCR reactions with
different analog concentrations and number of amplification
cycleswere pooled to give anerror rate ranging from0.2% to
5% [60] and cotransfected with gapped pPNL6 host vector
into the JAR200 yeast strain (gift of Andrew Rakestraw,
Massachusetts Institute of Technology) [3] by electropora-
tion to create a yeast surface display library of ~5 × 107
homologously recombined transformants [60]. The library
was enriched for brighter clones by three rounds of FACS as
previously described [3] using660 pMMG-11p, an analog to
MG-2p with 11 ethylene glycol monomers.
The Abysis Database1 was used to number the L5*
sequence according to Kabat [61], to identify CDRs, to
conduct BLAST searches (Fig. 1), and to obtain a statistical
measure of relatedness of its sequence to the family of
human λ class VL domains (Fig. S1) [62].
The affinity-matured FAPs derived from the progenitor L5
isolate [3] contain, in addition to the VL domain, additional
non-functional N-terminal residues derived from an adjacent
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These residues and theN-terminalHAandC-terminal c-myc
epitope tags were removed, and a C-terminal His6 tag was
inserted for purification. The secreted protein may contain
one or more N-terminal residues from an EAEAY cleavage
motif, recognized by the yeast KEX2secretion protease, that
was appended upstreamof the L5* coding region. The dimer
(dL5*), linked by a (GGGGS)4 spacer, was constructed by
PCR assembly [63] of an identical upstream L5* peptide that
was codon optimized for human/yeast expression to reduce
DNA sequence identity to ~72% to suppress intragenic
recombination; the two coding regions were assembled in
yeast by homologous recombination using long DNA
primers that encode the (GGGGS)4 linker. The four repeat
linker was chosen based on measurements of the L5*/MG
crystal structure, where the distance between linkable N-
andC-termini is ~36 Å.Using these samemethods,we then
built an analogous fused dimer, dL5**, which contains an
additional point mutation (Table 1).
Protein was secreted from yeast and purified as
previously described [3]. Purified L5* protein is soluble at
30 mg/ml in PBS and may be stored for extended periods
at 4 °C without aggregation. For biophysical assays, active
FAP dimer was quantitated by saturation titration with MG
(Ɛ = 91,700); the concentration of active protein was
defined as dye concentration at the extrapolated intersec-
tion between the linearly increasing signal observed at low
dye (excess protein) and the plateau observed at dye
saturation (excess dye). Concentration of active FAP
monomer was determined by comparison of monomer and
dimer slopes over the range 6–50 nm dye (protein in large
excess) where both slopes were increasing linearly,
assuming that two monomers give signal equal to one
dimer.Structure determination and refinement
Both the Fluidigm microfluidic crystallization system and
the JCSG/IAVI/TSRI Rigaku CrystalMation robot were
used to screen for initial crystallization conditions for L5*
(16.4 mg/ml) and its complex with MG (1:5 molar ratio of
protein to dye); crystals were obtained using both systems.
For unliganded L5* data collection, a crystal of the
unliganded protein was mounted directly from a 200-nl
sitting drop in a screening tray incubated at 20 °C using the
CrystalMation robot, with a well solution of 0.1 M sodium
acetate (pH 5) and 10% 2-methyl-2,3-pentanediol. The
crystal was cryoprotected with well solution containing
25% glycerol. The L5* crystal used for data collection was
grown at 22 °C in a Cryschem 24-well sitting-drop plate
(Hampton Research) with a well solution of 0.29 M
ammonium sulfate, 0.1 M sodium acetate (pH 4.5), and
drop formed by mixing 0.4 μl protein and 0.4 μl well
solution. The crystal was cryoprotected with well solution
containing 30% glycerol.
Data were collected for the unliganded and MG-bound
L5* at SSRL Beamline 11-1, using the automated crystal
mounter [64], Blu-Ice data collection software [65], and the
remote crystal screening and data collection system [66].
The unliganded crystals diffracted to a resolution of 1.95 Å,
while the dye-bound crystals diffracted to 2.45 Å. Data
integration and scaling were carried out with the HKL-2000
software suite [67], and the final data processing statistics
are shown in Table 2.The structure of the L5*/MG complex was determined
by molecular replacement using Phaser [68] and a VL
monomer from the highly related structure of the progenitor
L5 (our unpublished results) as a search model. Eight VL
monomers are found in the asymmetric unit, and Phaser
was used to first locate two VL subunits, which were
merged into one dimer search model that was then used to
find the remaining three copies of the dimer, for a final total
of four dimers. The structure of the unliganded L5* (two VL
monomers per asymmetric unit) was determined by
molecular replacement using Phaser and the refined VL
monomer from the L5*/MG structure as a search model.
Structure rebuilding was implemented with Coot [69], and
structures were refined by REFMAC [70] and PHENIX
[71]. Final refinement statistics are shown in Table 2.
L5* appears to be at least partially O-glycosylated at
Thr27, but the electron density is not well ordered for all
chains; one α-D-mannose has been modeled at this Thr27
on chains D, E, and H in the MG-bound structure and in
chain B in the unliganded structure. The AGA1p-AGA2p
agglutinin scaffold that displays L5* is extensively O-
glycosylated, a post-translational modification that is
common on yeast proteins that have transited the
secretory pathway. AGA2p, which is fused to the displayed
form of L5*, is O-mannosylated on at least 10 of the 21
available Ser/Thr motifs found on this 69-amino-acid
protein so that untreated purified protein migrates on
SDS PAGE gels at an apparent molecular weight (MW)
more than double the endoglycosidase-treated form [72].
L5* has four potential O-glycosylation motifs within the first
21 residues in addition to Thr27; these N-terminal residues
are all located on the outer surface of the homodimer distal
to the binding interface. Secreted purified L5* migrates on
an SDS gel at near the expected position, suggesting that
O-glycosylation is not extensive.
Contact analysis of L5* FAP and other VHVL or VLVL
variable domain complexes
Protein/protein and protein/ligand contacts of less than
or equal to 4 Å separation were identified, and pairwise
contact surface areas were calculated and classified by
bonding interactions on the SPACE server [73]. Amino
acid contact areas above a cutoff of 2 Å2 were subse-
quently mapped to CDRs that had been identified on the
SACS server [74].
Variable domain complexes in Fig. 3 and Fig. S3, identified
by their crystal structure PDB ID, are as follows: 2C1P,
anti-finrozole (drug candidate) [75]; 3CFB, anti-trans-stilbene
(blue fluorescent complex) [76]; 1FLR, anti-fluorescein
(quenched fluorescent dye) [77]; 1LVE, LEN myeloma VL
dimer [78]; 1QAC, LEN Q89L mutant VL dimer [24]; 2Q1E,
amyloidogenic mutant VL dimer [79]; 2RHE, Bence-Jones VL
dimer [80]; and 1IVL, synthetic VL dimer [81].Equilibrium binding analysis
Equilibrium titration assays employed 150 pM dL5* dimer
or 300 nM L5* monomer (150 nM dimer equivalent). Corre-
sponding samples of dye only were prepared as controls.
Samples were allowed to equilibrate for 15 h prior to reading
fluorescence; samples equilibrated for an additional 2 days
gave the same results. Background fluorescence signal was
4610 Malachite Green Dimerizes Antibody VL Domainssubtracted, and data were expressed in terms of the
concentration of formed complex. Data were analyzed by
non-linear regression fitting to a ligand depletion algorithm
usingGraphPadPrism5softwareaspreviously described [3].
The dissociation constant of the MG/dL5** complex was
determined as the ratio of koff to kon. Kinetic assays were
carried out on a Tecan Infinite M1000 microplate reader
equipped with injector in 96-well plates (Whatman Uniplate
Black) using top read fluorescence mode with reads at
intervals of 0.1–0.3 s; 50 μl of 4× final MG concentration
was injected at maximal rate (250 μl/s) into 150 μl of 1.33×
final FAP concentration so as to mix by turbulent flow. The
mixing/instrument delay prior to the first read is ~0.7 s.
On-rate time courses were performed three times (8.2 ±
0.3 × 106 l mol−1 s−1).
For off-rate measurements of dL5** binary complex,
200 nM dimer was equilibrated overnight with 300 nM MG
in a polypropylene microfuge tube. We spotted 2.0 μl of
assembled binary complex onto the bottom of a microplate
well and added 198 μl of 1.0 μM MG-QSY21 by hand,
followed by a 10-s shake. MG-QSY21 is a conjugate of MG
to a succinimidyl ester of QSY21 (Life Technologies
Q-20132). MG-QSY21 (1 μM) generates specific signal
from 2 nM dL5** at ~0.5% of the level generated by 2 nM
dL5**/MG complex. Off-rate time courses were performed
three times (1.5 ± 0.07 × 10−4 s−1).
For equilibrium assay of MG binding to L5*, ternary
complex was assembled in 1.5-ml microfuge tubes and
equilibrated for 14 h at 25° in the dark. The use of MG
ranging to 200 μM required procedures to mitigate the
inner filter effect. Fluorescence of 20-μl samples was top
read in a 96-well round-bottom microplate (Nunc 267342)
to reduce optical path length. The maximum absorbance of
assembled complex (635 nm) is 1.5-fold greater than
maximum absorbance of free dye (609 nm); at the 661 nm
excitation chosen here, the absorbance of the complex
increases to ~10.5-fold greater than that of free dye. A
correction curve was constructed from the fluorescence of
100 nM dL5* under these conditions; at 200 μM MG,
fluorescence was reduced to ~50%. Data were corrected
for background fluorescence of free dye, normalized to
FAP concentration, and plotted as fractional occupancy.
Co-plots of fractional occupancy generated by the exact
homodimerization algorithm {Eq. (17) in Mack et al. [37]}
were numerically calculated on an Excel spreadsheet
designed for this purpose and available for download
[37].Fluorescence spectra and quantum yield determination
Spectra (corrected emission) were taken on a Quanta-
master monochromator fluorimeter (Photon Technology
International) as previously described [3] using 1000 nM
MG and 3000 nM dL5* or 440 nM MG and 2200 nM L5*.
Quantum yields of 1000 nM MG in complex with 3000 nM
dL5* or 3000 nM dL5** were determined as previously
described [3] using Cy5.18 in PBS and cresyl violet in
MeOH as reference fluorophores.
Isothermal titration calorimetry
Isothermal titration calorimetry was carried out on a
MicroCal VP-ITC system in PBS+ buffer using 30 μM MGand 3.2 μM FAP (dimer equivalents). Background signal
(calculated as a mean value) generated by addition of MG
to buffer was subtracted prior to analysis on Origin 7 using
software supplied by the manufacturer.
Accession numbers
The coordinates and data have been submitted to
the Protein Data Bank, with accession codes 4K3G
(unliganded L5*) and 4K3H (MG-bound L5*).
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.jmb.2013.08.014.Acknowledgement
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